CRL News and Press, Charles River Laboratories International Inc. From 02/14/24

2024-02-14 13:19:02 ET Charles River Laboratories International, Inc. (CRL) Q4 2023 Results Conference Call February 14, 2024 08:30 AM ET Company Participants Todd Spencer - Vice President of Investor Relations James Foster - President and Chief Executive Officer ...

2024-02-14 07:17:20 ET More on Charles River Laboratories Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation Charles River Laboratories Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Charles River Laboratories Hi...

– Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP ...

Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...

2024-02-13 11:10:37 ET More on Charles River Laboratories Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation Seeking Alpha’s Quant Rating on Charles River Laboratories Historical earnings data for Charles River Laboratories ...

Endosafe ® Trillium™ recombinant cascade reagent (rCR) cartridges provide an alternative option to bolster commitments to sustainability and animal welfare Building upon its flagship Endosafe ® cartridge technology, Charles River Laboratories International, Inc....

2024-01-26 15:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commerc...

Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2023 financial results and provide 2024 guidance on Wednesday, February 14 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February...

2024-01-16 09:00:09 ET More on Charles River Laboratories Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation Charles River: Q3 Points To Ongoing Deterioration For further details see: Charles River Laboratories launches Rep/Cap plasmid